临床试验雷达

• Patients not eligible for PPCI.
• Patients who underwent thrombolytic therapy or received anti-thrombotics prior to hospital arrival.
• Prior coronary intervention: history of PCI or CABG.
• Known hematological disorders:

Thalassemia (microcytic anemia, normal iron profile, HbA2 ≥ 3.5% or elevated HbF).

Myelodysplastic syndromes (unexplained cytopenias with ≥10% dysplasia in bone marrow aspirate).

Leukemia (persistent leukocytosis or pancytopenia, blasts ≥20% in peripheral blood).

• Active infection or sepsis at admission (e.g., fever, leukocytosis, elevated CRP <100 mg/L without cardiac cause).
• Known autoimmune or chronic inflammatory diseases (e.g., systemic lupus erythematosus).
• Known or newly diagnosed malignancy.
• End-stage renal disease (eGFR <30 ml/min/1.73 m² or on dialysis).
• Advanced hepatic impairment (Child-Pugh class C; bilirubin >3 mg/dL or ALT/AST >3× upper limit of normal).
• Recent blood transfusion within 3 months.
• Recent use of steroids, chemotherapy, or immunosuppressive drugs.
• Mechanical complications or cardiogenic shock prior to or during STEMI presentation (e.g., papillary muscle rupture, ventricular septal defect, need for intra-aortic balloon pump).